Methiopropamine (MPA), a new psychoactive substance (NPS), is a stimulant drug, sold on its own or within a range of branded products.
Methiopropamine (MPA) is a thiophene ring-based structural analogue of methamphetamine which was originally reported in 1942.Chemically, it is not a phenethylamine or amphetamine, nor is it their functional analog.
Methiopropamine (MPA) is a stimulant (upper) drug with similar effects to methamphetamine which can make you feel alert and more energetic. It also increases your heart rate and breathing. People using it can experience a mild high, sexual arousal and loss of appetite as well as difficulty urinating (peeing), chest pain, breathing problems and an urge to re-dose.
Methiopropamine functions as a selective norepinephrine-dopamine releasing agent. This allows dopamine and norepinephrine to accumulate within the brain, resulting in stimulating and euphoric effects. It is approximately one third as potent as dextroamphetamine as a norepinephrine reuptake inhibitor and one fifth as much as a dopamine reuptake inhibitor. It displays negligible activity as a serotonin reuptake inhibitor.
Stimulation – In terms of its effects on the physical energy levels of the user, methiopropamine is usually considered to be mildly to moderately energetic and stimulating in a fashion that is considerably weaker in comparison to that of traditional recreational stimulants such as amphetamine, MDMA or cocaine. This encourages physical activities such as performing chores, repetitive tasks which would otherwise be boring and strenuous physical activities.
Spontaneous tactile sensations – The “body high” of methiopropamine can be described as an intense euphoric, sharp and all-encompassing tingling sensation that remains present through the duration of the experience.
Increased heart rate – In comparison to other stimulants such as amphetamine or cocaine, methiopropamine only has a mild effect on one’s heart rate.
Appetite suppression The above components are also accompanied by a suppression of appetite which is usually much less intense in strength in comparison to the appetite suppression experienced with amphetamine or methamphetamine.
Temperature regulation suppression
Teeth grinding – This component can be considered to be less intense when compared with that of MDMA.
MPA is described by many users as being similar to drugs such as caffeine or methylphenidate (Ritalin) and users state that they find it helpful when studying or working late. MPA reportedly induces very little euphoria. Comedown effects are usually described as minimal compared to some other substances, with effects including tiredness, low mood, headaches and irritability.
When MPA is combined with certain other drugs (for example aminoindanes, such as MDAI or 5-iAi) the user is placed at risk of serotonin toxicity. This can be fatal if not dealt with quickly. Symptoms include hyperthermia (overheating), hyperreflexia (over responsive reflexes), clonus (involuntary muscular contractions and relaxations), hypertension (high blood pressure), dysphoria (mental distress) and mydriasis (dilated pupils). Due to muscle tension being triggered by the condition, there is a potential of developing rhabdomyolysis (muscle tissue breakdown) which can cause severe kidney damage and can be fatal. It is therefore dangerous to restrain individuals, as increased agitation will lead to increased muscle tension trying to break free from restraints.